alexchang personal page - To The Moon

alexchang

No personal profile

0Follow

0Followers

0Topic

0Badge

2022-01-21

Thks

10 Biggest Price Target Changes For Thursday

2022-01-21

[Like] thks

Got $3,000? 5 Buffett Stocks to Buy and Hold Forever

2022-01-18

[Like] thks

2 Top Biotech Stocks to Buy and Hold for 10 Years

2022-01-16

[Like] thanks

Sorry, the original content has been removed

2022-01-14

[Like] tq

These Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet

2022-01-12

[Like]

Sorry, the original content has been removed

2022-01-11

[Like]

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3570706367093114","uuid":"3570706367093114","gmtCreate":1607768754645,"gmtModify":1607768754645,"name":"alexchang","pinyin":"alexchang","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9007943514,"gmtCreate":1642752586236,"gmtModify":1676533743080,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"Thks","listText":"Thks","text":"Thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9007943514","repostId":"1190196378","repostType":4,"repost":{"id":"1190196378","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1642682071,"share":"https://ttm.financial/m/news/1190196378?lang=&edition=fundamental","pubTime":"2022-01-20 20:34","market":"us","language":"en","title":"10 Biggest Price Target Changes For Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=1190196378","media":"Benzinga","summary":"Piper Sandler cut Advanced Micro Devices, Inc. price target from $140 to $130. AMD shares fell 1.3% ","content":"<html><head></head><body><ul><li>Piper Sandler cut <b>Advanced Micro Devices, Inc.</b> price target from $140 to $130. AMD shares fell 1.3% to $126.55 in pre-market trading.</li><li>BMO Capital boosted <b>Vertex Pharmaceuticals Incorporated</b> price target from $202 to $274. Vertex Pharmaceuticals shares rose 0.6% to $232.16 in pre-market trading.</li><li>Keybanc cut <b>Allbirds, Inc.</b> price target from $28 to $24. Allbirds shares rose 0.4% to $13.89 in pre-market trading.</li><li>Raymond James raised the price target for <b>Tenet Healthcare Corporation</b> from $105 to $120. Tenet Healthcare shares rose 2.1% to $78.75 in pre-market trading.</li></ul><ul><li>Keefe, Bruyette &amp; Woods reduced the price target on <b>U.S. Bancorp</b> from $73 to $64. U.S. Bancorp shares rose 0.4% to $57.60 in pre-market trading.</li><li>Goldman Sachs lowered the price target for <b>Silvergate Capital Corporation</b> from $190 to $166. Silvergate Capital shares rose 1.9% to $111.35 in pre-market trading.</li><li>Wells Fargo cut <b>Ashland Global Holdings Inc.</b> price target from $120 to $110. Ashland Global shares fell 0.9% to $99.00 in pre-market trading.</li><li>Piper Sandler lowered the price target on <b>NXP Semiconductors N.V.</b> from $235 to $210. NXP Semiconductors shares fell 1.5% to $207.78 in pre-market trading.</li><li>HC Wainwright &amp; Co. cut <b>Kintara Therapeutics, Inc.</b> price target from $6 to $3. Kintara Therapeutics shares rose 2.9% to $0.4403 in pre-market trading.</li><li>Keybanc lowered the price target on <b>Lyft, Inc.</b> from $72 to $65. Lyft shares fell 0.3% to $36.81 in pre-market trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-20 20:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><ul><li>Piper Sandler cut <b>Advanced Micro Devices, Inc.</b> price target from $140 to $130. AMD shares fell 1.3% to $126.55 in pre-market trading.</li><li>BMO Capital boosted <b>Vertex Pharmaceuticals Incorporated</b> price target from $202 to $274. Vertex Pharmaceuticals shares rose 0.6% to $232.16 in pre-market trading.</li><li>Keybanc cut <b>Allbirds, Inc.</b> price target from $28 to $24. Allbirds shares rose 0.4% to $13.89 in pre-market trading.</li><li>Raymond James raised the price target for <b>Tenet Healthcare Corporation</b> from $105 to $120. Tenet Healthcare shares rose 2.1% to $78.75 in pre-market trading.</li></ul><ul><li>Keefe, Bruyette &amp; Woods reduced the price target on <b>U.S. Bancorp</b> from $73 to $64. U.S. Bancorp shares rose 0.4% to $57.60 in pre-market trading.</li><li>Goldman Sachs lowered the price target for <b>Silvergate Capital Corporation</b> from $190 to $166. Silvergate Capital shares rose 1.9% to $111.35 in pre-market trading.</li><li>Wells Fargo cut <b>Ashland Global Holdings Inc.</b> price target from $120 to $110. Ashland Global shares fell 0.9% to $99.00 in pre-market trading.</li><li>Piper Sandler lowered the price target on <b>NXP Semiconductors N.V.</b> from $235 to $210. NXP Semiconductors shares fell 1.5% to $207.78 in pre-market trading.</li><li>HC Wainwright &amp; Co. cut <b>Kintara Therapeutics, Inc.</b> price target from $6 to $3. Kintara Therapeutics shares rose 2.9% to $0.4403 in pre-market trading.</li><li>Keybanc lowered the price target on <b>Lyft, Inc.</b> from $72 to $65. Lyft shares fell 0.3% to $36.81 in pre-market trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LYFT":"Lyft, Inc.","VRTX":"福泰制药","THC":"泰尼特","NXPI":"恩智浦","USB":"美国合众银行","AMD":"美国超微公司","BIRD":"Allbirds, Inc.","ASH":"亚什兰"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190196378","content_text":"Piper Sandler cut Advanced Micro Devices, Inc. price target from $140 to $130. AMD shares fell 1.3% to $126.55 in pre-market trading.BMO Capital boosted Vertex Pharmaceuticals Incorporated price target from $202 to $274. Vertex Pharmaceuticals shares rose 0.6% to $232.16 in pre-market trading.Keybanc cut Allbirds, Inc. price target from $28 to $24. Allbirds shares rose 0.4% to $13.89 in pre-market trading.Raymond James raised the price target for Tenet Healthcare Corporation from $105 to $120. Tenet Healthcare shares rose 2.1% to $78.75 in pre-market trading.Keefe, Bruyette & Woods reduced the price target on U.S. Bancorp from $73 to $64. U.S. Bancorp shares rose 0.4% to $57.60 in pre-market trading.Goldman Sachs lowered the price target for Silvergate Capital Corporation from $190 to $166. Silvergate Capital shares rose 1.9% to $111.35 in pre-market trading.Wells Fargo cut Ashland Global Holdings Inc. price target from $120 to $110. Ashland Global shares fell 0.9% to $99.00 in pre-market trading.Piper Sandler lowered the price target on NXP Semiconductors N.V. from $235 to $210. NXP Semiconductors shares fell 1.5% to $207.78 in pre-market trading.HC Wainwright & Co. cut Kintara Therapeutics, Inc. price target from $6 to $3. Kintara Therapeutics shares rose 2.9% to $0.4403 in pre-market trading.Keybanc lowered the price target on Lyft, Inc. from $72 to $65. Lyft shares fell 0.3% to $36.81 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9007943327,"gmtCreate":1642752224484,"gmtModify":1676533743071,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;thks","listText":"[Like]&nbsp;thks","text":"[Like] thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9007943327","repostId":"1190271564","repostType":4,"repost":{"id":"1190271564","kind":"news","pubTimestamp":1642663422,"share":"https://ttm.financial/m/news/1190271564?lang=&edition=fundamental","pubTime":"2022-01-20 15:23","market":"us","language":"en","title":"Got $3,000? 5 Buffett Stocks to Buy and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=1190271564","media":"Motley Fool","summary":"These Berkshire Hathaway-backed winners could supercharge your portfolio.","content":"<html><head></head><body><p>Warren Buffett stands atop the pantheon of history&#39;s most successful investors. If you were lucky enough to own a $3,000 stake in <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) when he took control of the company in 1965, that position would now be worth nearly $81 million.</p><p>The Oracle of Omaha&#39;s knack for finding high-quality long-term investment opportunities has led to market-crushing results, and his storied performance means the investing world tends to keep a close eye on his company&#39;s holdings. Let&#39;s take a closer look at five top stocks backed by Berkshire Hathaway that are worth buying and holding for the long term.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a99bd55ae86722cb44e242a3e8fcd151\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: THE MOTLEY FOOL.</span></p><p><b>1. Apple</b></p><p>With <b>Apple</b>&#39;s (NASDAQ:AAPL) share price having surged roughly 32.1% over the last year and the company currently sporting a market capitalization of more than $2.76 trillion, it&#39;s not unreasonable to look at the stock with a bit of a cautious eye. On the other hand, there&#39;s basically never been a bad time for<i>long-term</i>investors to buy the stock in the company&#39;s history.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/807818ed8a5e4c2574220b38b5cf3a64\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"/><span>AAPL DATA BY YCHARTS</span></p><p>Apple stands as the largest stock holding in the Berkshire portfolio, by far. Based on the last 13F filing from Buffett&#39;s company, the iPhone-maker accounts for nearly 43% of the investment conglomerate&#39;s stock holdings. That signifies an incredible vote of confidence from the modern era&#39;s most successful investor.</p><p>Between its market-leading mobile hardware and fast-growing software and services ecosystem, Apple&#39;s core businesses continue to look very strong, and it&#39;s likely that the company will also score wins in some exciting new fields. The California-based tech giant is already a leader in the wearable technology space, and it has huge opportunities in augmented reality hardware, autonomous electric vehicles, and other emerging product categories. The recent run-up in valuation means investors may want todollar-cost averageinto Apple stock, but the company looks well-positioned to continue growing over the long term.</p><p><b>2. Verizon</b></p><p>With a multi-billion-dollar investment in the fourth quarter of 2020, Berkshire Hathaway quickly made <b>Verizon Communications</b> (NYSE:VZ) one of its largest stock holdings. Internet communications are at the heart of modern business operations, and the telecom giant&#39;s top-rated service and infrastructure advantages should help it continue to be a category leader.</p><p>Verizon has been spending big to secure spectrum band and build out infrastructure for5G, but it&#39;s still in the early stages of benefiting from the rollout of the next-generation network technology. In addition to offering consumers a major leap forward with upload and download speeds, Verizon&#39;s 5G service will likely also help boost sales and earnings in the enterprise market.</p><p>With shares trading at roughly 10 times this year&#39;s expected earnings and sporting a 4.8% dividend yield, Verizon stock continues to look attractively valued. Investors even have a chance to buy the stock at prices lower than Berkshire got in at.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b30d6f848f83c57969cb29b9d24b3d1b\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"/><span>VZ DATA BY YCHARTS.</span></p><p><b>3. Snowflake</b></p><p>As a cloud software-as-a-service stock that trades at lofty price-to-sales multiple,<b>Snowflake</b> (NYSE:SNOW) is one of the more unusual companies in the Berkshire Hathaway portfolio. While the investment conglomerate has gradually been shifting more of its portfolio weight toward the technology sector, it&#39;s still pretty eye-catching to see Buffett get behind a company that trades at roughly 83 times this year&#39;s expected sales.</p><p>It&#39;s clear that the Oracle of Omaha and the investment team at Berkshire see something special in the data warehousing and analytics player. Snowflake&#39;s platform allows data to be gathered and analyzed from otherwise walled-off sources, enabling applications to have quick and easy access to a much wider spectrum of valuable information. The company offers category-leading service in its niche, and with more customers joining its platform and bringing along valuable data, it&#39;s benefiting from a network effect that could produce a powerful long-term moat.</p><p><b>4. Amazon</b></p><p>Perhaps more so than any other company,<b>Amazon</b>(NASDAQ:AMZN) is built to win the future. The company&#39;s core e-commerce and cloud infrastructure businesses look poised for strong growth over the long term as these industries continue to grow, and its core business pillars should provide the foundation for new growth bets that help the company continue to expand.</p><p>With a market cap of more than $1.6 trillion, Amazon is already a massive company, but it still has plenty of room for growth over the long term. The company&#39;s strength in e-commerce and cloud services has helped it rapidly build its position in the digital advertising market, and Amazon&#39;s excellent collection of resources and proven penchant for innovation suggest that it will be able to continue scoring wins in new categories that drive growth and complement its existing businesses.</p><p><b>5. Berkshire Hathaway</b></p><p>If you want to invest like Buffett, why limit yourself to picking just a handful of stocks in the Berkshire portfolio? Particularly when you can buy shares in Berkshire Hathaway directly and get exposure to all of the stocks in the company&#39;s portfolio, its subsidiaries, and its real estate, insurance, and energy businesses. In addition to Apple, Verizon, Amazon, and Snowflake, Berkshire Hathaway also owns substantial stakes in companies including <b>Bank of America</b>,<b>American Express</b>,<b>Coca-Cola</b>, and other industry-leading names.</p><p>Even after buying back more than $20 billion worth of its own stock last year, the investment conglomerate has a massive pool of resources and ended its third quarter with a record $149 billion in cash on the books. Owning Berkshire Hathaway stock means that when Buffett and his team of analysts go shopping with that money, your own portfolio gets exposure to those buys before they&#39;re made known to the public.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $3,000? 5 Buffett Stocks to Buy and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $3,000? 5 Buffett Stocks to Buy and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-20 15:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/19/got-3000-5-buffett-stocks-to-buy-and-hold-forever/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett stands atop the pantheon of history's most successful investors. If you were lucky enough to own a $3,000 stake in Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) when he took control of ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/19/got-3000-5-buffett-stocks-to-buy-and-hold-forever/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","SNOW":"Snowflake","BRK.B":"伯克希尔B","VZ":"威瑞森","BRK.A":"伯克希尔","AAPL":"苹果"},"source_url":"https://www.fool.com/investing/2022/01/19/got-3000-5-buffett-stocks-to-buy-and-hold-forever/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190271564","content_text":"Warren Buffett stands atop the pantheon of history's most successful investors. If you were lucky enough to own a $3,000 stake in Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) when he took control of the company in 1965, that position would now be worth nearly $81 million.The Oracle of Omaha's knack for finding high-quality long-term investment opportunities has led to market-crushing results, and his storied performance means the investing world tends to keep a close eye on his company's holdings. Let's take a closer look at five top stocks backed by Berkshire Hathaway that are worth buying and holding for the long term.IMAGE SOURCE: THE MOTLEY FOOL.1. AppleWith Apple's (NASDAQ:AAPL) share price having surged roughly 32.1% over the last year and the company currently sporting a market capitalization of more than $2.76 trillion, it's not unreasonable to look at the stock with a bit of a cautious eye. On the other hand, there's basically never been a bad time forlong-terminvestors to buy the stock in the company's history.AAPL DATA BY YCHARTSApple stands as the largest stock holding in the Berkshire portfolio, by far. Based on the last 13F filing from Buffett's company, the iPhone-maker accounts for nearly 43% of the investment conglomerate's stock holdings. That signifies an incredible vote of confidence from the modern era's most successful investor.Between its market-leading mobile hardware and fast-growing software and services ecosystem, Apple's core businesses continue to look very strong, and it's likely that the company will also score wins in some exciting new fields. The California-based tech giant is already a leader in the wearable technology space, and it has huge opportunities in augmented reality hardware, autonomous electric vehicles, and other emerging product categories. The recent run-up in valuation means investors may want todollar-cost averageinto Apple stock, but the company looks well-positioned to continue growing over the long term.2. VerizonWith a multi-billion-dollar investment in the fourth quarter of 2020, Berkshire Hathaway quickly made Verizon Communications (NYSE:VZ) one of its largest stock holdings. Internet communications are at the heart of modern business operations, and the telecom giant's top-rated service and infrastructure advantages should help it continue to be a category leader.Verizon has been spending big to secure spectrum band and build out infrastructure for5G, but it's still in the early stages of benefiting from the rollout of the next-generation network technology. In addition to offering consumers a major leap forward with upload and download speeds, Verizon's 5G service will likely also help boost sales and earnings in the enterprise market.With shares trading at roughly 10 times this year's expected earnings and sporting a 4.8% dividend yield, Verizon stock continues to look attractively valued. Investors even have a chance to buy the stock at prices lower than Berkshire got in at.VZ DATA BY YCHARTS.3. SnowflakeAs a cloud software-as-a-service stock that trades at lofty price-to-sales multiple,Snowflake (NYSE:SNOW) is one of the more unusual companies in the Berkshire Hathaway portfolio. While the investment conglomerate has gradually been shifting more of its portfolio weight toward the technology sector, it's still pretty eye-catching to see Buffett get behind a company that trades at roughly 83 times this year's expected sales.It's clear that the Oracle of Omaha and the investment team at Berkshire see something special in the data warehousing and analytics player. Snowflake's platform allows data to be gathered and analyzed from otherwise walled-off sources, enabling applications to have quick and easy access to a much wider spectrum of valuable information. The company offers category-leading service in its niche, and with more customers joining its platform and bringing along valuable data, it's benefiting from a network effect that could produce a powerful long-term moat.4. AmazonPerhaps more so than any other company,Amazon(NASDAQ:AMZN) is built to win the future. The company's core e-commerce and cloud infrastructure businesses look poised for strong growth over the long term as these industries continue to grow, and its core business pillars should provide the foundation for new growth bets that help the company continue to expand.With a market cap of more than $1.6 trillion, Amazon is already a massive company, but it still has plenty of room for growth over the long term. The company's strength in e-commerce and cloud services has helped it rapidly build its position in the digital advertising market, and Amazon's excellent collection of resources and proven penchant for innovation suggest that it will be able to continue scoring wins in new categories that drive growth and complement its existing businesses.5. Berkshire HathawayIf you want to invest like Buffett, why limit yourself to picking just a handful of stocks in the Berkshire portfolio? Particularly when you can buy shares in Berkshire Hathaway directly and get exposure to all of the stocks in the company's portfolio, its subsidiaries, and its real estate, insurance, and energy businesses. In addition to Apple, Verizon, Amazon, and Snowflake, Berkshire Hathaway also owns substantial stakes in companies including Bank of America,American Express,Coca-Cola, and other industry-leading names.Even after buying back more than $20 billion worth of its own stock last year, the investment conglomerate has a massive pool of resources and ended its third quarter with a record $149 billion in cash on the books. Owning Berkshire Hathaway stock means that when Buffett and his team of analysts go shopping with that money, your own portfolio gets exposure to those buys before they're made known to the public.","news_type":1},"isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004321080,"gmtCreate":1642513079686,"gmtModify":1676533717243,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;thks","listText":"[Like]&nbsp;thks","text":"[Like] thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004321080","repostId":"2204773593","repostType":4,"repost":{"id":"2204773593","kind":"highlight","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4139":"生物科技","REGN":"再生元制药公司","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005299079,"gmtCreate":1642301757420,"gmtModify":1676533699551,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;thanks","listText":"[Like]&nbsp;thanks","text":"[Like] thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005299079","repostId":"1122795028","repostType":4,"isVote":1,"tweetType":1,"viewCount":1016,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005996260,"gmtCreate":1642134745563,"gmtModify":1676533685395,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;tq","listText":"[Like]&nbsp;tq","text":"[Like] tq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005996260","repostId":"2203761497","repostType":4,"repost":{"id":"2203761497","kind":"highlight","pubTimestamp":1642122004,"share":"https://ttm.financial/m/news/2203761497?lang=&edition=fundamental","pubTime":"2022-01-14 09:00","market":"us","language":"en","title":"These Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet","url":"https://stock-news.laohu8.com/highlight/detail?id=2203761497","media":"Motley Fool","summary":"And they're built to remain among the world's fastest-growing companies as well.","content":"<html><head></head><body><p>Are you looking for raw rapid growth in your investments, even if that means dealing with (more than) a little extra volatility? It&#39;s understandable if you are.</p><p>If you&#39;ve got the time and intestinal fortitude to deal with a stock&#39;s big ups and downs, a big potential payoff awaits. The trick is simply finding picks with high-growth staying power.</p><p>Here are five such large-cap stocks to consider adding to your portfolio and sitting on for the next several years.</p><h2>1. Advanced Micro Devices</h2><p>If you think <b>Advanced Micro Devices</b> (NASDAQ:<a href=\"https://laohu8.com/S/AMD\">AMD</a>) is always behind <b>Nvidia</b> in the graphics card market while at the same time perpetually playing second fiddle to <b>Intel</b> within the computer processor arena, you&#39;re right.</p><p>But don&#39;t let AMD&#39;s lack of leadership of its two target markets distract you from the fact that AMD&#39;s smaller size can be a growth-driving advantage. Namely, Advanced Micro Devices&#39; hardware is a favorite among hardcore video gamers because it&#39;s affordable without sacrificing performance. Even though it&#39;s the second-biggest name in its two chief businesses, analysts are modeling top-line growth of 19% this year, which should drive 2021&#39;s expected per-share earnings of $2.63 up to $3.34 per share -- a 27% increase.</p><h2>2. Freeport-McMoRan</h2><p>Mining any sort of natural resource is a messy business, literally as well as figuratively. Permits and licensing are subject to social and political trends, and ongoing changes in the prices of hydrocarbons and metals can turn a profitable mining venture into an unprofitable <a href=\"https://laohu8.com/S/AONE.U\">one</a> at the drop of a hat.</p><p>If you can take a step back and look at the long-term picture, though, you&#39;ll likely see that the world&#39;s need for copper is never going to go away. If anything, it&#39;s only going to continue growing as we embrace more and more technologies like clean/green energy. CRU Group estimates the clean energy sector&#39;s need for the electricity-friendly metal will quintuple between 2020 and 2030, for instance.</p><p>Enter <b>Freeport-McMoRan</b> (NYSE:FCX). While it&#39;s a gold and molybdenum miner, the company is first and foremost a copper miner, selling a little over 1 billion pounds of the stuff during the third quarter of 2021 alone. Yet Freeport and its peers still can&#39;t keep up with demand.</p><p>Investors that have kept close tabs on Freeport-McMoRan -- and the copper industry as a whole -- will know that extreme price fluctuations have made things tough at times. In multi-year timeframes, though, copper prices have firmly improved, from less than $0.50 per pound in the 1980s and &#39;90s to more than $4 per pound now. <b>Goldman Sachs</b> forecasts its price will be near $7 per pound by 2025, boding very well for the biggest name in the business.</p><h2>3. Tesla</h2><p>To say last year was a good one for the electric vehicle (EV) market would be an understatement. Although 2020&#39;s pandemic-prompted lull helped statistically, year-over-year growth estimates for the worldwide sales of electric vehicles ranging from 80% to more than 100% (depending on the source) still carried the business to record-breaking unit deliveries of around 7 million, according to Rystad Energy.</p><p><b>Tesla</b> (NASDAQ:TSLA) carried more of that weight than any other EV maker, delivering 936,172 EVs in 2021, almost tripling its pre-pandemic 2019 output of 367,500 battery-powered vehicles. Look for more of the same sort of growth going forward, too, now that the global EV movement has developed some momentum. Analysts are calling for this year&#39;s sales to improve by $21 billion to reach $73 billion, driving a 40% profit increase as a result.</p><p>Astute investors may realize that Tesla is now losing market share to competitors that have finally started to manufacture rival EVs en masse. But it may not matter. The U.S. Energy Information Administration believes the world&#39;s total number of light-duty electric vehicles will swell from only a few million now to more than 670 million by 2050. Even capturing less than its fair share of that growth will be a boon for Tesla.</p><h2>4. The Trade Desk</h2><p><b>The Trade Desk</b> (NASDAQ:TTD) may not be a household name, but there&#39;s a good chance you or someone in your household has been affected by its service.</p><p>In simplest terms, The Trade Desk helps advertisers buy room, space, and time to present ads to consumers. The description doesn&#39;t quite do the company justice, though. In an arena that&#39;s increasingly distracting, The Trade Desk helps companies use digital data to deliver highly targeted advertisements without wasting money on ads that would do little good. Its Solimar software platform even makes it possible for an advertiser to use its own first-party data about a group of prospective customers.</p><p>This year&#39;s expected 30% sales growth is impressive. But even more impressive is that this pace of revenue growth merely extends a well-established and reliable growth streak that took root in 2016. It&#39;s a testament to how the marketing business has become more and more complicated as it&#39;s evolving into a technology-based endeavor.</p><h2>5. Repligen</h2><p>Finally, add <b>Repligen</b> (NASDAQ:RGEN) to your list of the market&#39;s fastest-growing large-cap stocks.</p><p>Repligen is a healthcare company, although it&#39;s not one most investors (or even patients) have heard of. It&#39;s more of a behind-the-scenes organization, supplying the industry with everything from dialysis solutions to gene therapy manufacturing tech to protein ligand resins used in the manufacturing of monoclonal antibodies. And yes, these resins are being used by drug companies making monoclonal antibodies to treat COVID-19 infections.</p><p>That&#39;s not necessarily the reason a growth-minded investor might want to step into this admittedly expensive stock, however; the COVID-19 pandemic should eventually come under control. Rather, Repligen&#39;s has some strong long-term growth prospects that could make this year&#39;s projected 20% sales growth the norm. That&#39;s because the coronavirus contagion is likely to have forever changed the pharmaceutical business&#39;s landscape. The bioprocessing of biologic drugs has been shown to do what vaccines can&#39;t, playing right into the hand Repligen is holding. Mordor Intelligence says the bioprocessing market will grow at an annualized clip of more than 11% through 2026. With minimal competition to deal with, though, Repligen is poised to win more than its fair share of this growth.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Are 5 of the Fastest-Growing Large-Cap Stocks on the Planet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-14 09:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/13/5-fastest-growing-large-cap-stocks/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Are you looking for raw rapid growth in your investments, even if that means dealing with (more than) a little extra volatility? It's understandable if you are.If you've got the time and intestinal ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/13/5-fastest-growing-large-cap-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4512":"苹果概念","AMD":"美国超微公司","BK4099":"汽车制造商","BK4548":"巴美列捷福持仓","TTD":"Trade Desk Inc.","BK4529":"IDC概念","BK4528":"SaaS概念","BK4023":"应用软件","TSLA":"特斯拉","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4555":"新能源车","BK4566":"资本集团","RGEN":"Repligen Corporation","BK4121":"生命科学工具和服务","BK4527":"明星科技股","FCX":"麦克莫兰铜金","BK4141":"半导体产品","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓","BK4015":"铜"},"source_url":"https://www.fool.com/investing/2022/01/13/5-fastest-growing-large-cap-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203761497","content_text":"Are you looking for raw rapid growth in your investments, even if that means dealing with (more than) a little extra volatility? It's understandable if you are.If you've got the time and intestinal fortitude to deal with a stock's big ups and downs, a big potential payoff awaits. The trick is simply finding picks with high-growth staying power.Here are five such large-cap stocks to consider adding to your portfolio and sitting on for the next several years.1. Advanced Micro DevicesIf you think Advanced Micro Devices (NASDAQ:AMD) is always behind Nvidia in the graphics card market while at the same time perpetually playing second fiddle to Intel within the computer processor arena, you're right.But don't let AMD's lack of leadership of its two target markets distract you from the fact that AMD's smaller size can be a growth-driving advantage. Namely, Advanced Micro Devices' hardware is a favorite among hardcore video gamers because it's affordable without sacrificing performance. Even though it's the second-biggest name in its two chief businesses, analysts are modeling top-line growth of 19% this year, which should drive 2021's expected per-share earnings of $2.63 up to $3.34 per share -- a 27% increase.2. Freeport-McMoRanMining any sort of natural resource is a messy business, literally as well as figuratively. Permits and licensing are subject to social and political trends, and ongoing changes in the prices of hydrocarbons and metals can turn a profitable mining venture into an unprofitable one at the drop of a hat.If you can take a step back and look at the long-term picture, though, you'll likely see that the world's need for copper is never going to go away. If anything, it's only going to continue growing as we embrace more and more technologies like clean/green energy. CRU Group estimates the clean energy sector's need for the electricity-friendly metal will quintuple between 2020 and 2030, for instance.Enter Freeport-McMoRan (NYSE:FCX). While it's a gold and molybdenum miner, the company is first and foremost a copper miner, selling a little over 1 billion pounds of the stuff during the third quarter of 2021 alone. Yet Freeport and its peers still can't keep up with demand.Investors that have kept close tabs on Freeport-McMoRan -- and the copper industry as a whole -- will know that extreme price fluctuations have made things tough at times. In multi-year timeframes, though, copper prices have firmly improved, from less than $0.50 per pound in the 1980s and '90s to more than $4 per pound now. Goldman Sachs forecasts its price will be near $7 per pound by 2025, boding very well for the biggest name in the business.3. TeslaTo say last year was a good one for the electric vehicle (EV) market would be an understatement. Although 2020's pandemic-prompted lull helped statistically, year-over-year growth estimates for the worldwide sales of electric vehicles ranging from 80% to more than 100% (depending on the source) still carried the business to record-breaking unit deliveries of around 7 million, according to Rystad Energy.Tesla (NASDAQ:TSLA) carried more of that weight than any other EV maker, delivering 936,172 EVs in 2021, almost tripling its pre-pandemic 2019 output of 367,500 battery-powered vehicles. Look for more of the same sort of growth going forward, too, now that the global EV movement has developed some momentum. Analysts are calling for this year's sales to improve by $21 billion to reach $73 billion, driving a 40% profit increase as a result.Astute investors may realize that Tesla is now losing market share to competitors that have finally started to manufacture rival EVs en masse. But it may not matter. The U.S. Energy Information Administration believes the world's total number of light-duty electric vehicles will swell from only a few million now to more than 670 million by 2050. Even capturing less than its fair share of that growth will be a boon for Tesla.4. The Trade DeskThe Trade Desk (NASDAQ:TTD) may not be a household name, but there's a good chance you or someone in your household has been affected by its service.In simplest terms, The Trade Desk helps advertisers buy room, space, and time to present ads to consumers. The description doesn't quite do the company justice, though. In an arena that's increasingly distracting, The Trade Desk helps companies use digital data to deliver highly targeted advertisements without wasting money on ads that would do little good. Its Solimar software platform even makes it possible for an advertiser to use its own first-party data about a group of prospective customers.This year's expected 30% sales growth is impressive. But even more impressive is that this pace of revenue growth merely extends a well-established and reliable growth streak that took root in 2016. It's a testament to how the marketing business has become more and more complicated as it's evolving into a technology-based endeavor.5. RepligenFinally, add Repligen (NASDAQ:RGEN) to your list of the market's fastest-growing large-cap stocks.Repligen is a healthcare company, although it's not one most investors (or even patients) have heard of. It's more of a behind-the-scenes organization, supplying the industry with everything from dialysis solutions to gene therapy manufacturing tech to protein ligand resins used in the manufacturing of monoclonal antibodies. And yes, these resins are being used by drug companies making monoclonal antibodies to treat COVID-19 infections.That's not necessarily the reason a growth-minded investor might want to step into this admittedly expensive stock, however; the COVID-19 pandemic should eventually come under control. Rather, Repligen's has some strong long-term growth prospects that could make this year's projected 20% sales growth the norm. That's because the coronavirus contagion is likely to have forever changed the pharmaceutical business's landscape. The bioprocessing of biologic drugs has been shown to do what vaccines can't, playing right into the hand Repligen is holding. Mordor Intelligence says the bioprocessing market will grow at an annualized clip of more than 11% through 2026. With minimal competition to deal with, though, Repligen is poised to win more than its fair share of this growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002635457,"gmtCreate":1641991166466,"gmtModify":1676533669368,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002635457","repostId":"1109557687","repostType":4,"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002025774,"gmtCreate":1641866334822,"gmtModify":1676533656863,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002025774","repostId":"2202277188","repostType":4,"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9005299079,"gmtCreate":1642301757420,"gmtModify":1676533699551,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;thanks","listText":"[Like]&nbsp;thanks","text":"[Like] thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005299079","repostId":"1122795028","repostType":4,"repost":{"id":"1122795028","kind":"news","pubTimestamp":1642293794,"share":"https://ttm.financial/m/news/1122795028?lang=&edition=fundamental","pubTime":"2022-01-16 08:43","market":"us","language":"en","title":"US IPO Week Ahead: Bitcoin Mining and Real Estate Lead a 5 IPO Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1122795028","media":"Renaissance Capital","summary":"Five IPOs are slated to raise $457 million in the shortened holiday week ahead.REIT Four Springs Cap","content":"<html><head></head><body><p>Five IPOs are slated to raise $457 million in the shortened holiday week ahead.</p><p>REIT <b>Four Springs Capital Trust</b>(FSPR) plans to raise $252 million at a $603 million market cap. The company’s portfolio consists of 156 commercial properties across 32 states, focused on single-tenant, income producing industrial, medical, retail, and office properties. Four Springs’ properties were 99.8% leased as of 12/15/21, though its 10 largest tenants accounted for nearly half of its ABR.</p><p>Bitcoin miner <b>Rhodium Enterprises</b>(RHDM) plans to raise $100 million at a $1.6 billion market cap. Rhodium believes it is one of the largest liquid-cooled bitcoin mining sites in the world, with 100 MW of liquid-cooled miners online as of 12/31/21. While the company depends on the volatile Bitcoin market, it delivered explosive growth and turned profitable in the 9mo21.</p><p><b>Verdant Earth Technologies</b>(VDNT) plans to raise $50 million at a $201 million market cap. Australia-based Verdant is a development stage green energy company in the process of repurposing and recommissioning a traditional coal-fired power plant to run on renewable fuel. The company does not expect to generate revenue until after it completes its first project, which depends on government approval.</p><p>OTC-listed <b>Modular Medical</b>(MODD) plans to raise $30 million at a $130 million market cap. Modular Medical is developing a wearable insulin pump device for both type 1 and type 2 diabetes, and expects to submit its product to the FDA in March 2022 through a premarket notification process. The company has not generated any revenues to date.</p><p><b>Samsara Vision</b>(SMSA) plans to raise $25 million at a $153 million market cap. This company produces medical implants for retinal diseases such as AMD. Highly unprofitable, Samsara’s current product line consists of two implantable miniature telescopes (IMT) and its Tsert delivery system.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: Bitcoin Mining and Real Estate Lead a 5 IPO Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: Bitcoin Mining and Real Estate Lead a 5 IPO Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-16 08:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90213/US-IPO-Week-Ahead-Bitcoin-mining-and-real-estate-lead-a-5-IPO-week><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Five IPOs are slated to raise $457 million in the shortened holiday week ahead.REIT Four Springs Capital Trust(FSPR) plans to raise $252 million at a $603 million market cap. The company’s portfolio ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90213/US-IPO-Week-Ahead-Bitcoin-mining-and-real-estate-lead-a-5-IPO-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MODD":"Modular Medical, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90213/US-IPO-Week-Ahead-Bitcoin-mining-and-real-estate-lead-a-5-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122795028","content_text":"Five IPOs are slated to raise $457 million in the shortened holiday week ahead.REIT Four Springs Capital Trust(FSPR) plans to raise $252 million at a $603 million market cap. The company’s portfolio consists of 156 commercial properties across 32 states, focused on single-tenant, income producing industrial, medical, retail, and office properties. Four Springs’ properties were 99.8% leased as of 12/15/21, though its 10 largest tenants accounted for nearly half of its ABR.Bitcoin miner Rhodium Enterprises(RHDM) plans to raise $100 million at a $1.6 billion market cap. Rhodium believes it is one of the largest liquid-cooled bitcoin mining sites in the world, with 100 MW of liquid-cooled miners online as of 12/31/21. While the company depends on the volatile Bitcoin market, it delivered explosive growth and turned profitable in the 9mo21.Verdant Earth Technologies(VDNT) plans to raise $50 million at a $201 million market cap. Australia-based Verdant is a development stage green energy company in the process of repurposing and recommissioning a traditional coal-fired power plant to run on renewable fuel. The company does not expect to generate revenue until after it completes its first project, which depends on government approval.OTC-listed Modular Medical(MODD) plans to raise $30 million at a $130 million market cap. Modular Medical is developing a wearable insulin pump device for both type 1 and type 2 diabetes, and expects to submit its product to the FDA in March 2022 through a premarket notification process. The company has not generated any revenues to date.Samsara Vision(SMSA) plans to raise $25 million at a $153 million market cap. This company produces medical implants for retinal diseases such as AMD. Highly unprofitable, Samsara’s current product line consists of two implantable miniature telescopes (IMT) and its Tsert delivery system.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1016,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002025774,"gmtCreate":1641866334822,"gmtModify":1676533656863,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002025774","repostId":"2202277188","repostType":4,"repost":{"id":"2202277188","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1641855743,"share":"https://ttm.financial/m/news/2202277188?lang=&edition=fundamental","pubTime":"2022-01-11 07:02","market":"us","language":"en","title":"US STOCKS-Nasdaq Ekes Out Gain in Late Session Comeback","url":"https://stock-news.laohu8.com/highlight/detail?id=2202277188","media":"Reuters","summary":"Wall Street's three major indexes staged a late-session comeback on Monday as the Nasdaq managed to ","content":"<html><head></head><body><p>Wall Street&#39;s three major indexes staged a late-session comeback on Monday as the Nasdaq managed to eke out a tiny gain and investors swooped in to hunt for bargains, while the S&amp;P 500 and the Dow Jones Industrial Average finished well above their session lows.</p><p>After falling almost 3% earlier in the day and as much as 10.37% below its intraday record level reached on Nov. 22, the technology-heavy Nasdaq pointed sharply higher to regain all its losses for the day in afternoon trading.</p><p>While investors spent the morning fretting about rising bond yields and what this week&#39;s inflation data might mean for U.S. Federal Reserve monetary policy tightening, others took advantage of earlier nerves to buy the dip.</p><p>&#34;We&#39;ve gotten to the point where you wonder if the roller coaster has peaked and is heading straight down. But fundamentally there&#39;s a lot of buyers in this market buying on the dip,&#34; said Rick Meckler, a partner of Cherry Lane Investments, a family investment office in New Vernon, New Jersey who attributed much of the afternoon strength to retail investors buying favorite stocks such as Tesla   .</p><p>Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago also attributed the late session comeback to dip-buyers looking at U.S. Treasury yields fall from their peaks of the day.</p><p>&#34;Some of the tech names are off 5 to 10 percent or more, and people are looking at that and going that looks pretty good - time to snap them up,&#34; said Nolte.</p><p>&#34;The other thing though to keep an eye on is what happens to interest rates because that has really been what&#39;s been dragging technology. We saw little bit of a reversal late in the day in (Treasury yields). They came down just a touch and that was a little bit of a green light for tech investors,&#34; he said.</p><p>The Dow Jones Industrial Average    fell 162.79 points, or 0.45%, to 36,068.87, the S&amp;P 500    lost 6.74 points, or 0.14%, to 4,670.29 and the Nasdaq Composite    added 6.93 points, or 0.05%, to 14,942.83.</p><p>After starting the day among the biggest laggards, the S&amp;P technology index managed to eke out a tiny gain of 0.1%, behind the healthcare sector which closed up 1% and ahead of communications services which, rising 0.02%, was the session&#39;s only other gainer among the 11 major industry sectors.</p><p>The biggest decliners on the day were industrials which closed down 1.2% and materials which dropped 0.99%.</p><p>Traders have ramped up their rate hike expectations since the Fed&#39;s minutes from the December meeting appeared to signal an earlier-than-expected rate rise.</p><p>Goldman Sachs said it expects the Fed to raise rates four times in 2022, compared to its previous forecast of three.</p><p>Earlier the benchmark 10-year Treasury yield rose to its highest level in nearly two years on Monday.</p><p>After falling as much as 4.6% earlier in the session, Nasdaq heavyweight Tesla made a dramatic turnaround to close up 3%.</p><p>Meckler said retail investors appeared to flood back into the stock which had suffered after Chief Executive Elon Musk tweeted on Friday that the electric carmaker will raise the U.S. price of its advanced driver assistant software.</p><p>Nike shares closed down 4.2% after HSBC downgraded the stock to &#34;hold.&#34;</p><p>Declining issues outnumbered advancing ones on the NYSE by a 2.04-to-1 ratio; on Nasdaq, a 1.97-to-1 ratio favored decliners.</p><p>The S&amp;P 500 posted 38 new 52-week highs and 5 new lows; the Nasdaq Composite recorded 69 new highs and 609 new lows.</p><p>On U.S. exchanges 12.15 billion shares changed hands compared with the 10.55 billion average for the last 20 sessions.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US STOCKS-Nasdaq Ekes Out Gain in Late Session Comeback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS STOCKS-Nasdaq Ekes Out Gain in Late Session Comeback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-11 07:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Wall Street&#39;s three major indexes staged a late-session comeback on Monday as the Nasdaq managed to eke out a tiny gain and investors swooped in to hunt for bargains, while the S&amp;P 500 and the Dow Jones Industrial Average finished well above their session lows.</p><p>After falling almost 3% earlier in the day and as much as 10.37% below its intraday record level reached on Nov. 22, the technology-heavy Nasdaq pointed sharply higher to regain all its losses for the day in afternoon trading.</p><p>While investors spent the morning fretting about rising bond yields and what this week&#39;s inflation data might mean for U.S. Federal Reserve monetary policy tightening, others took advantage of earlier nerves to buy the dip.</p><p>&#34;We&#39;ve gotten to the point where you wonder if the roller coaster has peaked and is heading straight down. But fundamentally there&#39;s a lot of buyers in this market buying on the dip,&#34; said Rick Meckler, a partner of Cherry Lane Investments, a family investment office in New Vernon, New Jersey who attributed much of the afternoon strength to retail investors buying favorite stocks such as Tesla   .</p><p>Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago also attributed the late session comeback to dip-buyers looking at U.S. Treasury yields fall from their peaks of the day.</p><p>&#34;Some of the tech names are off 5 to 10 percent or more, and people are looking at that and going that looks pretty good - time to snap them up,&#34; said Nolte.</p><p>&#34;The other thing though to keep an eye on is what happens to interest rates because that has really been what&#39;s been dragging technology. We saw little bit of a reversal late in the day in (Treasury yields). They came down just a touch and that was a little bit of a green light for tech investors,&#34; he said.</p><p>The Dow Jones Industrial Average    fell 162.79 points, or 0.45%, to 36,068.87, the S&amp;P 500    lost 6.74 points, or 0.14%, to 4,670.29 and the Nasdaq Composite    added 6.93 points, or 0.05%, to 14,942.83.</p><p>After starting the day among the biggest laggards, the S&amp;P technology index managed to eke out a tiny gain of 0.1%, behind the healthcare sector which closed up 1% and ahead of communications services which, rising 0.02%, was the session&#39;s only other gainer among the 11 major industry sectors.</p><p>The biggest decliners on the day were industrials which closed down 1.2% and materials which dropped 0.99%.</p><p>Traders have ramped up their rate hike expectations since the Fed&#39;s minutes from the December meeting appeared to signal an earlier-than-expected rate rise.</p><p>Goldman Sachs said it expects the Fed to raise rates four times in 2022, compared to its previous forecast of three.</p><p>Earlier the benchmark 10-year Treasury yield rose to its highest level in nearly two years on Monday.</p><p>After falling as much as 4.6% earlier in the session, Nasdaq heavyweight Tesla made a dramatic turnaround to close up 3%.</p><p>Meckler said retail investors appeared to flood back into the stock which had suffered after Chief Executive Elon Musk tweeted on Friday that the electric carmaker will raise the U.S. price of its advanced driver assistant software.</p><p>Nike shares closed down 4.2% after HSBC downgraded the stock to &#34;hold.&#34;</p><p>Declining issues outnumbered advancing ones on the NYSE by a 2.04-to-1 ratio; on Nasdaq, a 1.97-to-1 ratio favored decliners.</p><p>The S&amp;P 500 posted 38 new 52-week highs and 5 new lows; the Nasdaq Composite recorded 69 new highs and 609 new lows.</p><p>On U.S. exchanges 12.15 billion shares changed hands compared with the 10.55 billion average for the last 20 sessions.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯","TSLA":"特斯拉"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2202277188","content_text":"Wall Street's three major indexes staged a late-session comeback on Monday as the Nasdaq managed to eke out a tiny gain and investors swooped in to hunt for bargains, while the S&P 500 and the Dow Jones Industrial Average finished well above their session lows.After falling almost 3% earlier in the day and as much as 10.37% below its intraday record level reached on Nov. 22, the technology-heavy Nasdaq pointed sharply higher to regain all its losses for the day in afternoon trading.While investors spent the morning fretting about rising bond yields and what this week's inflation data might mean for U.S. Federal Reserve monetary policy tightening, others took advantage of earlier nerves to buy the dip.\"We've gotten to the point where you wonder if the roller coaster has peaked and is heading straight down. But fundamentally there's a lot of buyers in this market buying on the dip,\" said Rick Meckler, a partner of Cherry Lane Investments, a family investment office in New Vernon, New Jersey who attributed much of the afternoon strength to retail investors buying favorite stocks such as Tesla   .Paul Nolte, portfolio manager at Kingsview Investment Management in Chicago also attributed the late session comeback to dip-buyers looking at U.S. Treasury yields fall from their peaks of the day.\"Some of the tech names are off 5 to 10 percent or more, and people are looking at that and going that looks pretty good - time to snap them up,\" said Nolte.\"The other thing though to keep an eye on is what happens to interest rates because that has really been what's been dragging technology. We saw little bit of a reversal late in the day in (Treasury yields). They came down just a touch and that was a little bit of a green light for tech investors,\" he said.The Dow Jones Industrial Average    fell 162.79 points, or 0.45%, to 36,068.87, the S&P 500    lost 6.74 points, or 0.14%, to 4,670.29 and the Nasdaq Composite    added 6.93 points, or 0.05%, to 14,942.83.After starting the day among the biggest laggards, the S&P technology index managed to eke out a tiny gain of 0.1%, behind the healthcare sector which closed up 1% and ahead of communications services which, rising 0.02%, was the session's only other gainer among the 11 major industry sectors.The biggest decliners on the day were industrials which closed down 1.2% and materials which dropped 0.99%.Traders have ramped up their rate hike expectations since the Fed's minutes from the December meeting appeared to signal an earlier-than-expected rate rise.Goldman Sachs said it expects the Fed to raise rates four times in 2022, compared to its previous forecast of three.Earlier the benchmark 10-year Treasury yield rose to its highest level in nearly two years on Monday.After falling as much as 4.6% earlier in the session, Nasdaq heavyweight Tesla made a dramatic turnaround to close up 3%.Meckler said retail investors appeared to flood back into the stock which had suffered after Chief Executive Elon Musk tweeted on Friday that the electric carmaker will raise the U.S. price of its advanced driver assistant software.Nike shares closed down 4.2% after HSBC downgraded the stock to \"hold.\"Declining issues outnumbered advancing ones on the NYSE by a 2.04-to-1 ratio; on Nasdaq, a 1.97-to-1 ratio favored decliners.The S&P 500 posted 38 new 52-week highs and 5 new lows; the Nasdaq Composite recorded 69 new highs and 609 new lows.On U.S. exchanges 12.15 billion shares changed hands compared with the 10.55 billion average for the last 20 sessions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":351,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9007943327,"gmtCreate":1642752224484,"gmtModify":1676533743071,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;thks","listText":"[Like]&nbsp;thks","text":"[Like] thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9007943327","repostId":"1190271564","repostType":4,"isVote":1,"tweetType":1,"viewCount":769,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005996260,"gmtCreate":1642134745563,"gmtModify":1676533685395,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;tq","listText":"[Like]&nbsp;tq","text":"[Like] tq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005996260","repostId":"2203761497","repostType":4,"isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9007943514,"gmtCreate":1642752586236,"gmtModify":1676533743080,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"Thks","listText":"Thks","text":"Thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9007943514","repostId":"1190196378","repostType":4,"isVote":1,"tweetType":1,"viewCount":579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9004321080,"gmtCreate":1642513079686,"gmtModify":1676533717243,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;thks","listText":"[Like]&nbsp;thks","text":"[Like] thks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9004321080","repostId":"2204773593","repostType":4,"repost":{"id":"2204773593","kind":"highlight","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<html><head></head><body><p>Time is one of an investor&#39;s greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.</p><p>That&#39;s why it&#39;s essential to ignore short-term volatility and instead focus on companies&#39; long-term prospects. With that said, let&#39;s look at two biotech stocks that have the tools to produce above-average returns over the next decade: <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a> and <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a>.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/69325802609adcc2f37ebbf961855011\" tg-width=\"720\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>MRNA data by YCharts</span></p><p>1. <a href=\"https://laohu8.com/S/MRNA\"><b>Moderna</b> </a></p><p>Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna&#39;s COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren&#39;t in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.</p><p>As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.</p><p>Moderna won&#39;t let all this money go to waste, and it is advancing several exciting candidates. The company&#39;s pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.</p><p>That&#39;s not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.</p><p>Although Moderna&#39;s shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company&#39;s forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech&#39;s industry average of 11.2.</p><p>While the company&#39;s stock may see tougher times once its coronavirus tailwind ends -- which won&#39;t happen anytime soon -- Moderna&#39;s long-term prospects look bright.</p><p>2. <a href=\"https://laohu8.com/S/REGN\"><b>Regeneron</b> </a></p><p>Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech&#39;s revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.</p><p>Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both <b>Merck</b> and <b>Pfizer</b> recently earned authorization for their respective products in this space.</p><p>However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won&#39;t drop off a cliff. Indeed, management has high hopes for the product.</p><p>To quote Regeneron&#39;s CEO, Leonard Schleifer: &#34;Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.&#34;</p><p>But Regeneron isn&#39;t just a coronavirus play. In Q3, the company&#39;s revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.</p><p>For a biotech company of this size, that&#39;s still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while <b>Bayer</b> markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.</p><p>Regeneron&#39;s sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron&#39;s future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4139":"生物科技","REGN":"再生元制药公司","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002635457,"gmtCreate":1641991166466,"gmtModify":1676533669368,"author":{"id":"3570706367093114","authorId":"3570706367093114","name":"alexchang","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570706367093114","authorIdStr":"3570706367093114"},"themes":[],"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002635457","repostId":"1109557687","repostType":4,"repost":{"id":"1109557687","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641534283,"share":"https://ttm.financial/m/news/1109557687?lang=&edition=fundamental","pubTime":"2022-01-07 13:44","market":"us","language":"en","title":"US Banks Q4 Earnings Preview: JPM, WFC, C, MS, and GS","url":"https://stock-news.laohu8.com/highlight/detail?id=1109557687","media":"Tiger Newspress","summary":"While a few companies’ results have been trickling in already, Q4 earnings season kicks off in earne","content":"<html><head></head><body><p>While a few companies’ results have been trickling in already, Q4 earnings season kicks off in earnest starting on January 14th, when the major US banks start to report. As the repository for excess cash and the go-to place for new loans, banks serve as a bellwether for the “Main Street” economy as a whole.</p><p><b>Big U.S. banks expected to post uptick in core Q4 revenues on economic rebound</b></p><p>Analysts expect big U.S. banks to show an uptick in fourth quarter core revenues thanks to new lending and firming Treasury yields even while headline earnings will be mixed on differences in how each institution accounted for pandemic loan losses.</p><p>On Friday, JPMorgan Chase &amp; Co and Citigroup Inc are expected to post roughly 20% and 30% declines, respectively, in profits compared with the year-earlier quarter, while Bank of America Corp&#39;s profits will be up 20% when it reports on Jan. 19, according to analyst estimates compiled by Refinitiv as of Friday.</p><p>Wells Fargo &amp; Co, which also reports on Friday, is expected to show a 67% jump in profits.</p><p>That mixed performance will be largely due to the different pace at which banks started reversing accounting charges for pandemic-related loan losses which have not materialized. Other complicating factors are restructuring costs and asset sales at Citigroup and Wells Fargo.</p><p>Goldman Sachs Group Inc and Morgan Stanley, meanwhile, are expected to report fourth-quarter profit declines of about 7% and 2%, respectively, as revenue from fixed-income trading income dipped from exceptional levels.</p><p>Broadly speaking, however, the picture is likely to be positive and analysts anticipate that bank executives will sound an optimistic note on the outlook for core earnings.</p><p>Operating profits are expected to rise as the continued economic recovery boosted loan growth and as yields from banks&#39; Treasury securities edged up, or at least held steady, during the quarter.</p><p>&#34;If investors look under the hood, there is much good to be seen,&#34; Odeon Capital Group analyst Dick Bove wrote in note on Thursday.</p><p>Overall, core profits for big banks will be up about 6% on average after stripping out loan loss provisions, taxes and unusual items, Goldman Sachs analyst Richard Ramsden estimated.</p><p>More consumers and businesses returned to their banks for credit during the fourth quarter after being propped up last year by government stimulus programs, analysts said.</p><p>Core loan balances at banks increased about 4% in the fourth quarter, the fastest growth in nearly two years, according to estimates by Deutsche Bank analyst Matt O&#39;Connor, based on Fed data through Dec. 22. That strength came from both consumer credit card and business lending, he wrote in a note.</p><p>The quarter also offered a taste of the higher net interest income that could come as Treasury yields rise in 2022, according to Gerard Cassidy of RBC Capital Markets.</p><p>The difference in average daily yields between shorter- and longer-term government securities, known as the yield curve, increased slightly during the quarter.</p><p>Betting on these positive trends, investors pushed the KBW Bank Index up 35% in 2021, easily beating the S&amp;P 500&#39;s 27% gain.</p><p>&#34;A late pick-up in loan growth in 4Q, coupled with a recent rise in interest rates bode well for bank (guidance) on net interest income in 1Q22 and for the full year,&#34; wrote O&#39;Connor.</p><p>With the economic outlook uncertain due to inflation and the Omicron COVID-19 variant, however, some investors are cautious on buying more bank stocks.</p><p>Doubts are growing about the Fed&#39;s ability to maintain the economic recovery on which lending growth relies after the central bank last week released minutes from its latest policy meeting that showed officials might raise interest rates sooner than expected to slow inflation.</p><p>Jason Ware, chief investment officer for Albion Financial Group, said he is evaluating whether to buy more bank stocks but is hesitant, partly due to caution about whether higher yields are sustainable.</p><p>He&#39;s mindful, too, he added, of history suggesting that &#34;bank stocks do better going into rate hikes than they do during rate hikes.&#34;</p><p><b>The good times will continue into 2022</b></p><p>Yet, many analysts think the good times will continue into 2022 and beyond, as several factors are putting a tailwind behind many banks.</p><p>For starters, economic activity continues to pick up in the U.S. and around the world, as total lockdowns due to the coronavirus pandemic become less and less likely.</p><p>Next, with inflation picking up significantly, the Federal Reserve Board seems likely to raise interest rates many times in 2022, which should help bank margins.</p><p>Rising interest rates benefit banks in several ways. For instance, the cost of borrowing will go up for consumers in the form of higher rates on credit cards and certain mortgages. In turn, this boosts banks’ profitability.</p><p><b>Five US banks in focus</b></p><p><b>JPMorgan Chase- Reports January 14th</b></p><p><b>Q4 Expectation: $2.965 in EPS, $29.931B in revenues</b></p><p>JPMorgan Chase &amp; Co. last issued its earnings data on October 13th, 2021. The financial services provider reported $3.74 earnings per share (EPS) for the quarter, beating analysts&#39; consensus estimates of $3.00 by $0.74. The firm had revenue of $29.60 billion for the quarter, compared to the consensus estimate of $29.63 billion. Its quarterly revenue was down 1.0% on a year-over-year basis. JPMorgan Chase &amp; Co. has generated $15.81 earnings per share over the last year ($15.81 diluted earnings per share) and currently has a price-to-earnings ratio of 10.5. Earnings for JPMorgan Chase &amp; Co. are expected to decrease by -20.51% in the coming year, from $14.97 to $11.90 per share.</p><p><b>Wells Fargo - Reports January 14th</b></p><p><b>Q4 Expectation: $0.999 in EPS, $18.837B in revenues</b></p><p>Wells Fargo &amp; Company last posted its earnings data on October 14th, 2021. The financial services provider reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.18. The company had revenue of $18.83 billion for the quarter, compared to analyst estimates of $18.31 billion. Its quarterly revenue was down .1% compared to the same quarter last year. Wells Fargo &amp; Company has generated $4.24 earnings per share over the last year ($4.24 diluted earnings per share) and currently has a price-to-earnings ratio of 12.6. Earnings for Wells Fargo &amp; Company are expected to decrease by -19.18% in the coming year, from $4.64 to $3.75 per share.</p><p><b>Citigroup (C) - Reports January 14th</b></p><p><b>Q4 Expectation: $1.72 in EPS, $17.015B in revenues</b></p><p>Citigroup last announced its earnings results on October 14th, 2021. The reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.23. The business had revenue of $17.15 billion for the quarter, compared to the consensus estimate of $16.93 billion. Its revenue for the quarter was down .9% compared to the same quarter last year. Citigroup has generated $10.70 earnings per share over the last year ($10.70 diluted earnings per share) and currently has a price-to-earnings ratio of 6.1. Earnings for Citigroup are expected to decrease by -26.02% in the coming year, from $10.80 to $7.99 per share.</p><p><b>Goldman Sachs- Reports January 18th</b></p><p><b>Q4 Expectation: $11.681 in EPS, $11.989B in revenues</b></p><p>The Goldman Sachs Group last issued its quarterly earnings results on October 14th, 2021. The investment management company reported $14.93 earnings per share for the quarter, topping the consensus estimate of $9.78 by $5.15. The company had revenue of $13.61 billion for the quarter, compared to analysts&#39; expectations of $11.61 billion. Its revenue for the quarter was up 26.2% on a year-over-year basis. The Goldman Sachs Group has generated $60.63 earnings per share over the last year ($60.63 diluted earnings per share) and currently has a price-to-earnings ratio of 6.5. Earnings for The Goldman Sachs Group are expected to decrease by -34.18% in the coming year, from $60.65 to $39.92 per share.</p><p><b>Morgan Stanley- Reports January 19th</b></p><p><b>Q4 Expectation: $1.91 in EPS, $14.357B in revenues</b></p><p>Morgan Stanley last posted its earnings results on October 14th, 2021. The financial services provider reported $1.98 earnings per share for the quarter, topping analysts&#39; consensus estimates of $1.68 by $0.30. The firm had revenue of $14.75 billion for the quarter, compared to analysts&#39; expectations of $13.95 billion. Its quarterly revenue was up 26.6% compared to the same quarter last year. Morgan Stanley has generated $7.83 earnings per share over the last year ($7.83 diluted earnings per share) and currently has a price-to-earnings ratio of 13.2. Earnings for Morgan Stanley are expected to decrease by -7.28% in the coming year, from $7.97 to $7.39 per share.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US Banks Q4 Earnings Preview: JPM, WFC, C, MS, and GS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS Banks Q4 Earnings Preview: JPM, WFC, C, MS, and GS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-07 13:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>While a few companies’ results have been trickling in already, Q4 earnings season kicks off in earnest starting on January 14th, when the major US banks start to report. As the repository for excess cash and the go-to place for new loans, banks serve as a bellwether for the “Main Street” economy as a whole.</p><p><b>Big U.S. banks expected to post uptick in core Q4 revenues on economic rebound</b></p><p>Analysts expect big U.S. banks to show an uptick in fourth quarter core revenues thanks to new lending and firming Treasury yields even while headline earnings will be mixed on differences in how each institution accounted for pandemic loan losses.</p><p>On Friday, JPMorgan Chase &amp; Co and Citigroup Inc are expected to post roughly 20% and 30% declines, respectively, in profits compared with the year-earlier quarter, while Bank of America Corp&#39;s profits will be up 20% when it reports on Jan. 19, according to analyst estimates compiled by Refinitiv as of Friday.</p><p>Wells Fargo &amp; Co, which also reports on Friday, is expected to show a 67% jump in profits.</p><p>That mixed performance will be largely due to the different pace at which banks started reversing accounting charges for pandemic-related loan losses which have not materialized. Other complicating factors are restructuring costs and asset sales at Citigroup and Wells Fargo.</p><p>Goldman Sachs Group Inc and Morgan Stanley, meanwhile, are expected to report fourth-quarter profit declines of about 7% and 2%, respectively, as revenue from fixed-income trading income dipped from exceptional levels.</p><p>Broadly speaking, however, the picture is likely to be positive and analysts anticipate that bank executives will sound an optimistic note on the outlook for core earnings.</p><p>Operating profits are expected to rise as the continued economic recovery boosted loan growth and as yields from banks&#39; Treasury securities edged up, or at least held steady, during the quarter.</p><p>&#34;If investors look under the hood, there is much good to be seen,&#34; Odeon Capital Group analyst Dick Bove wrote in note on Thursday.</p><p>Overall, core profits for big banks will be up about 6% on average after stripping out loan loss provisions, taxes and unusual items, Goldman Sachs analyst Richard Ramsden estimated.</p><p>More consumers and businesses returned to their banks for credit during the fourth quarter after being propped up last year by government stimulus programs, analysts said.</p><p>Core loan balances at banks increased about 4% in the fourth quarter, the fastest growth in nearly two years, according to estimates by Deutsche Bank analyst Matt O&#39;Connor, based on Fed data through Dec. 22. That strength came from both consumer credit card and business lending, he wrote in a note.</p><p>The quarter also offered a taste of the higher net interest income that could come as Treasury yields rise in 2022, according to Gerard Cassidy of RBC Capital Markets.</p><p>The difference in average daily yields between shorter- and longer-term government securities, known as the yield curve, increased slightly during the quarter.</p><p>Betting on these positive trends, investors pushed the KBW Bank Index up 35% in 2021, easily beating the S&amp;P 500&#39;s 27% gain.</p><p>&#34;A late pick-up in loan growth in 4Q, coupled with a recent rise in interest rates bode well for bank (guidance) on net interest income in 1Q22 and for the full year,&#34; wrote O&#39;Connor.</p><p>With the economic outlook uncertain due to inflation and the Omicron COVID-19 variant, however, some investors are cautious on buying more bank stocks.</p><p>Doubts are growing about the Fed&#39;s ability to maintain the economic recovery on which lending growth relies after the central bank last week released minutes from its latest policy meeting that showed officials might raise interest rates sooner than expected to slow inflation.</p><p>Jason Ware, chief investment officer for Albion Financial Group, said he is evaluating whether to buy more bank stocks but is hesitant, partly due to caution about whether higher yields are sustainable.</p><p>He&#39;s mindful, too, he added, of history suggesting that &#34;bank stocks do better going into rate hikes than they do during rate hikes.&#34;</p><p><b>The good times will continue into 2022</b></p><p>Yet, many analysts think the good times will continue into 2022 and beyond, as several factors are putting a tailwind behind many banks.</p><p>For starters, economic activity continues to pick up in the U.S. and around the world, as total lockdowns due to the coronavirus pandemic become less and less likely.</p><p>Next, with inflation picking up significantly, the Federal Reserve Board seems likely to raise interest rates many times in 2022, which should help bank margins.</p><p>Rising interest rates benefit banks in several ways. For instance, the cost of borrowing will go up for consumers in the form of higher rates on credit cards and certain mortgages. In turn, this boosts banks’ profitability.</p><p><b>Five US banks in focus</b></p><p><b>JPMorgan Chase- Reports January 14th</b></p><p><b>Q4 Expectation: $2.965 in EPS, $29.931B in revenues</b></p><p>JPMorgan Chase &amp; Co. last issued its earnings data on October 13th, 2021. The financial services provider reported $3.74 earnings per share (EPS) for the quarter, beating analysts&#39; consensus estimates of $3.00 by $0.74. The firm had revenue of $29.60 billion for the quarter, compared to the consensus estimate of $29.63 billion. Its quarterly revenue was down 1.0% on a year-over-year basis. JPMorgan Chase &amp; Co. has generated $15.81 earnings per share over the last year ($15.81 diluted earnings per share) and currently has a price-to-earnings ratio of 10.5. Earnings for JPMorgan Chase &amp; Co. are expected to decrease by -20.51% in the coming year, from $14.97 to $11.90 per share.</p><p><b>Wells Fargo - Reports January 14th</b></p><p><b>Q4 Expectation: $0.999 in EPS, $18.837B in revenues</b></p><p>Wells Fargo &amp; Company last posted its earnings data on October 14th, 2021. The financial services provider reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.18. The company had revenue of $18.83 billion for the quarter, compared to analyst estimates of $18.31 billion. Its quarterly revenue was down .1% compared to the same quarter last year. Wells Fargo &amp; Company has generated $4.24 earnings per share over the last year ($4.24 diluted earnings per share) and currently has a price-to-earnings ratio of 12.6. Earnings for Wells Fargo &amp; Company are expected to decrease by -19.18% in the coming year, from $4.64 to $3.75 per share.</p><p><b>Citigroup (C) - Reports January 14th</b></p><p><b>Q4 Expectation: $1.72 in EPS, $17.015B in revenues</b></p><p>Citigroup last announced its earnings results on October 14th, 2021. The reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.23. The business had revenue of $17.15 billion for the quarter, compared to the consensus estimate of $16.93 billion. Its revenue for the quarter was down .9% compared to the same quarter last year. Citigroup has generated $10.70 earnings per share over the last year ($10.70 diluted earnings per share) and currently has a price-to-earnings ratio of 6.1. Earnings for Citigroup are expected to decrease by -26.02% in the coming year, from $10.80 to $7.99 per share.</p><p><b>Goldman Sachs- Reports January 18th</b></p><p><b>Q4 Expectation: $11.681 in EPS, $11.989B in revenues</b></p><p>The Goldman Sachs Group last issued its quarterly earnings results on October 14th, 2021. The investment management company reported $14.93 earnings per share for the quarter, topping the consensus estimate of $9.78 by $5.15. The company had revenue of $13.61 billion for the quarter, compared to analysts&#39; expectations of $11.61 billion. Its revenue for the quarter was up 26.2% on a year-over-year basis. The Goldman Sachs Group has generated $60.63 earnings per share over the last year ($60.63 diluted earnings per share) and currently has a price-to-earnings ratio of 6.5. Earnings for The Goldman Sachs Group are expected to decrease by -34.18% in the coming year, from $60.65 to $39.92 per share.</p><p><b>Morgan Stanley- Reports January 19th</b></p><p><b>Q4 Expectation: $1.91 in EPS, $14.357B in revenues</b></p><p>Morgan Stanley last posted its earnings results on October 14th, 2021. The financial services provider reported $1.98 earnings per share for the quarter, topping analysts&#39; consensus estimates of $1.68 by $0.30. The firm had revenue of $14.75 billion for the quarter, compared to analysts&#39; expectations of $13.95 billion. Its quarterly revenue was up 26.6% compared to the same quarter last year. Morgan Stanley has generated $7.83 earnings per share over the last year ($7.83 diluted earnings per share) and currently has a price-to-earnings ratio of 13.2. Earnings for Morgan Stanley are expected to decrease by -7.28% in the coming year, from $7.97 to $7.39 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WFC":"富国银行","GS":"高盛","JPM":"摩根大通","MS":"摩根士丹利","C":"花旗"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109557687","content_text":"While a few companies’ results have been trickling in already, Q4 earnings season kicks off in earnest starting on January 14th, when the major US banks start to report. As the repository for excess cash and the go-to place for new loans, banks serve as a bellwether for the “Main Street” economy as a whole.Big U.S. banks expected to post uptick in core Q4 revenues on economic reboundAnalysts expect big U.S. banks to show an uptick in fourth quarter core revenues thanks to new lending and firming Treasury yields even while headline earnings will be mixed on differences in how each institution accounted for pandemic loan losses.On Friday, JPMorgan Chase & Co and Citigroup Inc are expected to post roughly 20% and 30% declines, respectively, in profits compared with the year-earlier quarter, while Bank of America Corp's profits will be up 20% when it reports on Jan. 19, according to analyst estimates compiled by Refinitiv as of Friday.Wells Fargo & Co, which also reports on Friday, is expected to show a 67% jump in profits.That mixed performance will be largely due to the different pace at which banks started reversing accounting charges for pandemic-related loan losses which have not materialized. Other complicating factors are restructuring costs and asset sales at Citigroup and Wells Fargo.Goldman Sachs Group Inc and Morgan Stanley, meanwhile, are expected to report fourth-quarter profit declines of about 7% and 2%, respectively, as revenue from fixed-income trading income dipped from exceptional levels.Broadly speaking, however, the picture is likely to be positive and analysts anticipate that bank executives will sound an optimistic note on the outlook for core earnings.Operating profits are expected to rise as the continued economic recovery boosted loan growth and as yields from banks' Treasury securities edged up, or at least held steady, during the quarter.\"If investors look under the hood, there is much good to be seen,\" Odeon Capital Group analyst Dick Bove wrote in note on Thursday.Overall, core profits for big banks will be up about 6% on average after stripping out loan loss provisions, taxes and unusual items, Goldman Sachs analyst Richard Ramsden estimated.More consumers and businesses returned to their banks for credit during the fourth quarter after being propped up last year by government stimulus programs, analysts said.Core loan balances at banks increased about 4% in the fourth quarter, the fastest growth in nearly two years, according to estimates by Deutsche Bank analyst Matt O'Connor, based on Fed data through Dec. 22. That strength came from both consumer credit card and business lending, he wrote in a note.The quarter also offered a taste of the higher net interest income that could come as Treasury yields rise in 2022, according to Gerard Cassidy of RBC Capital Markets.The difference in average daily yields between shorter- and longer-term government securities, known as the yield curve, increased slightly during the quarter.Betting on these positive trends, investors pushed the KBW Bank Index up 35% in 2021, easily beating the S&P 500's 27% gain.\"A late pick-up in loan growth in 4Q, coupled with a recent rise in interest rates bode well for bank (guidance) on net interest income in 1Q22 and for the full year,\" wrote O'Connor.With the economic outlook uncertain due to inflation and the Omicron COVID-19 variant, however, some investors are cautious on buying more bank stocks.Doubts are growing about the Fed's ability to maintain the economic recovery on which lending growth relies after the central bank last week released minutes from its latest policy meeting that showed officials might raise interest rates sooner than expected to slow inflation.Jason Ware, chief investment officer for Albion Financial Group, said he is evaluating whether to buy more bank stocks but is hesitant, partly due to caution about whether higher yields are sustainable.He's mindful, too, he added, of history suggesting that \"bank stocks do better going into rate hikes than they do during rate hikes.\"The good times will continue into 2022Yet, many analysts think the good times will continue into 2022 and beyond, as several factors are putting a tailwind behind many banks.For starters, economic activity continues to pick up in the U.S. and around the world, as total lockdowns due to the coronavirus pandemic become less and less likely.Next, with inflation picking up significantly, the Federal Reserve Board seems likely to raise interest rates many times in 2022, which should help bank margins.Rising interest rates benefit banks in several ways. For instance, the cost of borrowing will go up for consumers in the form of higher rates on credit cards and certain mortgages. In turn, this boosts banks’ profitability.Five US banks in focusJPMorgan Chase- Reports January 14thQ4 Expectation: $2.965 in EPS, $29.931B in revenuesJPMorgan Chase & Co. last issued its earnings data on October 13th, 2021. The financial services provider reported $3.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.74. The firm had revenue of $29.60 billion for the quarter, compared to the consensus estimate of $29.63 billion. Its quarterly revenue was down 1.0% on a year-over-year basis. JPMorgan Chase & Co. has generated $15.81 earnings per share over the last year ($15.81 diluted earnings per share) and currently has a price-to-earnings ratio of 10.5. Earnings for JPMorgan Chase & Co. are expected to decrease by -20.51% in the coming year, from $14.97 to $11.90 per share.Wells Fargo - Reports January 14thQ4 Expectation: $0.999 in EPS, $18.837B in revenuesWells Fargo & Company last posted its earnings data on October 14th, 2021. The financial services provider reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.18. The company had revenue of $18.83 billion for the quarter, compared to analyst estimates of $18.31 billion. Its quarterly revenue was down .1% compared to the same quarter last year. Wells Fargo & Company has generated $4.24 earnings per share over the last year ($4.24 diluted earnings per share) and currently has a price-to-earnings ratio of 12.6. Earnings for Wells Fargo & Company are expected to decrease by -19.18% in the coming year, from $4.64 to $3.75 per share.Citigroup (C) - Reports January 14thQ4 Expectation: $1.72 in EPS, $17.015B in revenuesCitigroup last announced its earnings results on October 14th, 2021. The reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.23. The business had revenue of $17.15 billion for the quarter, compared to the consensus estimate of $16.93 billion. Its revenue for the quarter was down .9% compared to the same quarter last year. Citigroup has generated $10.70 earnings per share over the last year ($10.70 diluted earnings per share) and currently has a price-to-earnings ratio of 6.1. Earnings for Citigroup are expected to decrease by -26.02% in the coming year, from $10.80 to $7.99 per share.Goldman Sachs- Reports January 18thQ4 Expectation: $11.681 in EPS, $11.989B in revenuesThe Goldman Sachs Group last issued its quarterly earnings results on October 14th, 2021. The investment management company reported $14.93 earnings per share for the quarter, topping the consensus estimate of $9.78 by $5.15. The company had revenue of $13.61 billion for the quarter, compared to analysts' expectations of $11.61 billion. Its revenue for the quarter was up 26.2% on a year-over-year basis. The Goldman Sachs Group has generated $60.63 earnings per share over the last year ($60.63 diluted earnings per share) and currently has a price-to-earnings ratio of 6.5. Earnings for The Goldman Sachs Group are expected to decrease by -34.18% in the coming year, from $60.65 to $39.92 per share.Morgan Stanley- Reports January 19thQ4 Expectation: $1.91 in EPS, $14.357B in revenuesMorgan Stanley last posted its earnings results on October 14th, 2021. The financial services provider reported $1.98 earnings per share for the quarter, topping analysts' consensus estimates of $1.68 by $0.30. The firm had revenue of $14.75 billion for the quarter, compared to analysts' expectations of $13.95 billion. Its quarterly revenue was up 26.6% compared to the same quarter last year. Morgan Stanley has generated $7.83 earnings per share over the last year ($7.83 diluted earnings per share) and currently has a price-to-earnings ratio of 13.2. Earnings for Morgan Stanley are expected to decrease by -7.28% in the coming year, from $7.97 to $7.39 per share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}